Vertex Pharmaceuticals
Update in progressVRTX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Vertex Pharmaceuticals is a U.S.-based biotechnology company focused on serious diseases, especially cystic fibrosis, sickle cell disease, transfusion dependent beta thalassemia, and acute pain. It markets CF medicines including TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, and is developing CASGEVY, JOURNAVX, VX-522, inaxaplin, VX-264, VX-670, and VX-407. Customers include specialty pharmacies, distributors, hospitals, and clinics. Founded 1989, Boston.
Company score
- Sentiment
- 2.17
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.05
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 1.16
- Governance
- 0.54
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.48
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 1.32
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Reshma Kewalramani FASN, M.D.
- Founded1989
- Employees6,400
- Websitewww.vrtx.com
Identifiers
- ISINUS92532F1003
- FIGIBBG000C1S2X2
- LEI54930015RAQRRZ5ZGJ91
- CUSIP92532F100
- CIK0000875320